文献速递浆细胞疾病

抗CD38单克隆抗体清除CD38阳性调节性T细胞可使浆细胞病患者对SARS-CoV-2疫苗接种产生持久应答

Depletion of CD38-positive regulatory T cells by anti-CD38 monoclonal antibodies induces a durable response to SARS-CoV-2 vaccination in patients with plasma cell dyscrasia.
PubMed 文献 · Br J Haematol · 2022-02-16

本研究在60例浆细胞病患者中探讨CD38阳性调节性T细胞(Treg)与mRNA-COVID-19疫苗接种的关系。接受抗CD38单克隆抗体治疗者CD38阳性Treg显著低于未接受者(0.9 vs. 13.2/μl)。迟发应答者CD38阳性Treg计数显著低于非迟发应答者(2.5 vs. 10.3/μl),且CD38阳性Treg较低者抗体滴度从第4-12周维持,较高者则下降。

要点

  • 抗CD38单克隆抗体治疗者CD38阳性Treg显著低于未治疗者(0.9 vs. 13.2/μl)。
  • 迟发应答者CD38阳性Treg显著低于非迟发应答者(2.5 vs. 10.3/μl)。
  • CD38阳性Treg较低者抗体滴度从第4-12周维持,较高者下降。

核心结论

  • 抗CD38单克隆抗体清除CD38阳性Treg可能使浆细胞病患者对mRNA-COVID-19疫苗接种产生持久应答。

研究设计与样本

  • 本研究在60例浆细胞病患者中分析CD38阳性调节性T细胞与mRNA-COVID-19疫苗接种的关系。

主要发现

  • 接受抗CD38单克隆抗体治疗者CD38阳性Treg显著低于未接受者(0.9 vs. 13.2/μl)。
  • 迟发应答者(第二剂疫苗接种后第4-12周抗体滴度升高)CD38阳性Treg计数显著低于非迟发应答者(2.5 vs. 10.3/μl)。
  • CD38阳性Treg水平较低的患者抗体滴度从第4-12周维持,而CD38阳性Treg水平较高的患者抗体滴度下降。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study reports the relationship between CD38+ regulatory T cells (Tregs) and messenger RNA coronavirus disease 2019 (mRNA-COVID-19) vaccination in 60 patients with plasma cell dyscrasia. Patients treated with anti-CD38 monoclonal antibodies (mAbs) had significantly lower CD38+ Tregs than those not treated (0.9 vs. 13.2/μl). Late-responders, whose antibody titres increased from weeks 4-12 after the second vaccination, had significantly lower CD38+ Treg counts than non-late-responders (2.5 vs. 10.3/μl). Antibody titres in patients with lower CD38+ Treg levels were maintained from weeks 4-12 but decreased in those with higher CD38+ Treg levels. Therefore, depletion of CD38+ Tregs by anti-CD38 mAbs may induce a durable response to mRNA-COVID-19 vaccination.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Terao T, Naduka T, Ikeda D, et al. Depletion of CD38-positive regulatory T cells by anti-CD38 monoclonal antibodies induces a durable response to SARS-CoV-2 vaccination in patients with plasma cell dyscrasia. Br J Haematol. 2022. PMID: 35172374. doi:10.1111/bjh.18079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。